ERICA FARRAR: Open Payments
NPI 1962574939 · MARIETTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,991 in 133 payments from 20 companies in 2025. Trend: 2023 $2,169 · 2024 $2,290 · 2025 $2,991
Food & beverage: $2,991
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 35 | $657 |
| GENZYME CORPORATION | 18 | $451 |
| AstraZeneca Pharmaceuticals LP | 16 | $337 |
| Regeneron Healthcare Solutions, Inc. | 11 | $322 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $261 |
| Verona Pharma, Inc. | 6 | $184 |
| Electromed, Inc. | 8 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Grifols USA, LLC | 3 | $74 |
| CSL Behring | 3 | $74 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, Ohtuvayre, OFEV, TRELEGY ELLIPTA, FASENRA, SMARTVEST.
Industry payments across GA — which companies pay providers there.
